Organisation paid for research Program year 2025 Source: CMS Open Payments

Genesiscare-Plantation

Neither a doctor nor a teaching hospital

Research payments

$876,565

713 payments

Through program year 2025, Genesiscare-Plantation is reported as receiving $876,565 in research payments, across 713 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$92,044	88
2024	Research	$191,414	158
2023	Research	$571,040	457
2022	Research	$22,067	10

Breakdown

Who paid Research payments · program years 2022–2025

Bayer HealthCare Pharmaceuticals Inc. $876,565 713 payments

Studies the money was for Research payments · program years 2022–2025

Open-label external control arm study of darolutamide plus A $593,107 467 payments
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC $163,821 193 payments
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned $63,637 52 payments
BAY 888223, Long Term Safety of Radium 223 in Castrate Resistant Prostate Cancer (CRPC) patients with bones metastasis in Routine Clinical Practice Settings $56,000 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.